Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations: 2014-2024

Historic Cash from Operations for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to -$274.9 million.

  • Syndax Pharmaceuticals' Cash from Operations fell 13.18% to -$70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$310.9 million, marking a year-over-year decrease of 20.09%. This contributed to the annual value of -$274.9 million for FY2024, which is 71.17% down from last year.
  • According to the latest figures from FY2024, Syndax Pharmaceuticals' Cash from Operations is -$274.9 million, which was down 71.17% from -$160.6 million recorded in FY2023.
  • Syndax Pharmaceuticals' Cash from Operations' 5-year high stood at $29.1 million during FY2021, with a 5-year trough of -$274.9 million in FY2024.
  • In the last 3 years, Syndax Pharmaceuticals' Cash from Operations had a median value of -$160.6 million in 2023 and averaged -$189.7 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Cash from Operations surged by 140.88% in 2021, and later plummeted by 558.88% in 2022.
  • Syndax Pharmaceuticals' Cash from Operations (Yearly) stood at -$71.3 million in 2020, then surged by 140.88% to $29.1 million in 2021, then tumbled by 558.88% to -$133.7 million in 2022, then decreased by 20.14% to -$160.6 million in 2023, then slumped by 71.17% to -$274.9 million in 2024.